Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
Top Cited Papers
- 20 December 2006
- journal article
- neurooncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (36) , 5711-5715
- https://doi.org/10.1200/jco.2006.08.2941
Abstract
Purpose: The purpose of this study was to analyze prognostic factors for patients with newly diagnosed primary CNS lymphoma (PCNSL) in order to establish a predictive model that could be applied to the care of patients and the design of prospective clinical trials. Patients and Methods: Three hundred thirty-eight consecutive patients with newly diagnosed PCNSL seen at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY) between 1983 and 2003 were analyzed. Standard univariate and multivariate analyses were performed. In addition, a formal cut point analysis was used to determine the most statistically significant cut point for age. Recursive partitioning analysis (RPA) was used to create independent prognostic classes. An external validation set obtained from three prospective Radiation Therapy Oncology Group (RTOG) PCNSL clinical trials was used to test the RPA classification. Results: Age and performance status were the only variables identified on standard multivariate analysis. Cut point analysis of age determined that patients age ≤ 50 years had significantly improved outcome compared with older patients. RPA of 282 patients identified three distinct prognostic classes: class 1 (patients < 50 years), class 2 (patients ≥50; Karnofsky performance score [KPS] ≥ 70) and class 3 (patients ≥ 50; KPS < 70). These three classes significantly distinguished outcome with regard to both overall and failure-free survival. Analysis of the RTOG data set confirmed the validity of this classification. Conclusion: The MSKCC prognostic score is a simple, statistically powerful model with universal applicability to patients with newly diagnosed PCNSL. We recommend that it be adopted for the management of newly diagnosed patients and incorporated into the design of prospective clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Trends in survival from primary central nervous system lymphoma, 1975–1999Cancer, 2005
- The treatment of primary central nervous system lymphoma in 122 immunocompetent patientsCancer, 2005
- Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factorsInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group ExperienceJournal of Clinical Oncology, 2003
- Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10Journal of Clinical Oncology, 2002
- Treatment for Primary CNS Lymphoma: The Next StepJournal of Clinical Oncology, 2000
- Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastasesInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Primary central nervous system lymphoma: age and performance status are more important than treatment modalityInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Validation and Predictive Power of Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis Classes for Malignant Glioma Patients: A Report Using RTOG 90-06☆International Journal of Radiation Oncology*Biology*Physics, 1998
- Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation therapy Oncology Group (RTOG): RTOG 8315International Journal of Radiation Oncology*Biology*Physics, 1992